[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neoplasms-prostate\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neoplasms-prostate":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,70,103,141],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100618502","phase-1-first-time-in-human-study-of-gsk5471713-in-adults-with-mcrpc-100618502",false,"NCT07332455","First-Time-in-Human Study of GSK5471713 in Adults With mCRPC","A Phase 1\u002F2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Dose Optimization Study of GSK5471713 in Adult Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)","Inclusion Criteria:\n\n* Participants with mCRPC that have histologically or cytologically confirmed adenocarcinoma of the prostate.\n* Participants with mCRPC that has prostate cancer progression while on Androgen deprivation therapy (ADT).\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.\n* Progression on ADT and \\>=1 prior Androgen receptor pathway inhibitors (ARPI) for Hormone-Sensitive Prostate Cancer (HSPC) or Castration resistant prostate cancer (CRPC) and received 1-2 prior taxane based chemotherapy regimens.\n\nExclusion Criteria:\n\n* Pathological finding consistent with small cell, neuroendocrine carcinoma of the prostate, or any histology different from adenocarcinoma.\n* Impaired cardiac function or clinically significant cardiac disease.\n* Any significant medical condition, such as uncontrolled infection or clinically significant laboratory abnormality.\n* Prior therapy with Androgen receptor (AR) Degrader targeted therapy. Other protocol-defined inclusion\u002Fexclusion criteria apply.","MALE","18 Years",{"count":19,"type":20},54,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit\u002Frisk of GSK5471713 given as a monotherapy in mCRPC.",[27],"Neoplasms, Prostate",[29,30,31,32],"Metastatic castration-resistant prostate cancer","First-Time-in-Human","GSK5471713","Prostate cancer","RECRUITING","2026-06-17",{"date":36,"type":37},"2026-06-18","ACTUAL",{"date":39,"type":37},"2026-02-10",{"date":41,"type":20},"2030-03-26",{"name":43,"class":44},"GlaxoSmithKline","INDUSTRY",8,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100592242","phase-1-a-study-of-gsk5458514-administered-alone-or-in-combination-with-other-anti-cancer-agents-in-participants-with-prostate-cancer-100592242","NCT06990880","A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer","A Phase 1\u002F2 First-Time-In-Human, Open-Label, Multicenter, Dose Escalation and Expansion Study of GSK5458514 PSMA Targeting T Cell Engager Alone or in Combination With Other Anti-Cancer Agents in Adult Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","Inclusion Criteria:\n\n* Provide signed informed consent. Participants must be capable of providing informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.\n* Male participants ≥18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of signing the ICF.\n\nMale participants are eligible to participate if they agree to the following during the study intervention period and for at least 195 days, after the last dose of study intervention:\n\nRefrain from donating sperm\n\nPLUS either:\n\nBe abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent.\n\nOR\n\nMust agree to use contraception as detailed below:\n\nAgree to use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant.\n\n* Participants with mCRPC:\n\n  * Histologically or cytologically confirmed adenocarcinoma of the prostate\n  * Metastatic disease diagnosed either by radiologic imaging (Positron emission tomography \\[PET\\]- Computed tomography \\[CT\\]) and\u002For regular CT and\u002For Magnetic resonance imaging (MRI) and\u002For bone scan\n  * Castration-resistant status as per PCWG3 criteria\n* Has prior novel anti-androgen receptor therapy failure and had treatment failure with 1-2 taxane-based chemotherapy regimens including for metastatic hormone sensitive prostate cancer.\n* Has (1) at least 1 soft tissue target lesion per Prostate Cancer Working Group 3 (PCWG3)-modified Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) OR (2) if Non-Target soft tissue disease only per PCWG3-modified RECIST 1.1, may be included if a rise in PSA on 2 successive determinations at least 1 week apart (the most recent screening measurement must have been ≥ 2 ng\u002FmL) with testosterone levels \\\u003C50 ng\u002FdL, OR (3) bone disease defined by PCWG3 (2 or more lesions on bone scan at screening), as determined by the investigator.\n* Documented disease progression on most recent systemic therapy defined by fulfilling at least 1 of the PCWG3 criteria\n* Have serum testosterone \\\u003C50 ng\u002FdL (\\\u003C1.7 nM). Patients must have undergone bilateral orchiectomy or be on continuous androgen-deprivation therapy with a GnRH agonist or antagonist; this therapy must have been initiated at least 4 weeks prior to randomization and treatment must be continued throughout the study.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤1, with no deterioration in the 2 weeks before step-up treatment period Day 1.\n* Have supplied tumor tissue from a newly obtained biopsy or archival tumor tissue for retrospective detection of Prostate-specific membrane antigen (PSMA) expression and other biomarker analysis. Tissue from a newly obtained biopsy is preferred. If a newly obtained biopsy is not feasible, archival tumor tissue preferably taken after the completion of the participant's last line of therapy prior to the first dose of study drug is acceptable.\n* Participants must have adequate organ function\n\nExclusion Criteria:\n\n* Pathological finding consistent with small cell, neuroendocrine carcinoma of the prostate or any histology different from adenocarcinoma.\n* History of central nervous system (CNS) metastases or leptomeningeal disease.\n* Diagnosis of invasive malignancy or history of invasive malignancy other than the disease under study within the last 5 years, except as noted below:\n\n  * History of an invasive malignancy for which the participant was definitively treated, and in which the participant has been disease free for at least 2 years, and which, in the opinion of the principal investigator and medical monitor, is not expected to affect the evaluation of the effects of the study intervention on the currently targeted disease under study\n  * Curatively treated basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, and\u002For in situ breast cancer may be enrolled\n  * • Has ongoing adverse reaction(s) from prior therapy that have not recovered to ≤Grade 1 or to the baseline status preceding prior therapy, excluding \\[e.g., alopecia, hearing loss, vitiligo, endocrinopathy managed with replacement therapy, and Grade 2 neuropathy\\], or that the investigator, with the agreement of the sponsor, considers to be not clinically relevant for the tolerability of study intervention in the current clinical study.\n* Confirmed history or recurrent autoimmune disease that has required systemic treatments in the 2 years prior to screening. Participants with prior history of autoimmune disease must be discussed with the medical monitor. Replacement therapy is not considered a form of systemic therapy (e.g., thyroid hormone for autoimmune thyroiditis or insulin is not exclusionary).\n* Has evidence of interstitial lung disease, non-infectious pneumonitis, and\u002For a history of interstitial lung disease, non-infectious pneumonitis that required steroid .\n* Any anti-cancer therapy or prior systemic biologic therapy, including immunotherapy within 4 weeks of start dose.\n* Prior PSMA radionuclide therapy within 2 months prior to GSK5458514 unless participant received \\\u003C2 cycles.\n* Prior PSMA-Chimeric antigen receptor T cell therapy (CAR-T) cell therapy and PSMA (T cell engager) TCE\u002F Bispecific T cell engagers (BiTE) or other prostate Tumor-associated antigens (TAA) specific T cell engager (TCE).\n* Has any history of prior allogenic or autologous bone marrow transplant or other solid organ transplant.\n* Has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.\n* History of severe neurological or psychiatric disorder, including epilepsy, dementia, or major depression deemed to interfere with study assessments.\n* Has had any major surgery (such as craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks prior to first dose of study intervention.\n* Serious infections within 4 weeks prior to the first dose, including but not limited to infectious complications, bacteremia, severe pneumonia treated with IV antibiotics for ≥2 weeks; active infections with therapeutic IV antibiotics within 2 weeks prior to the first dose or oral antibiotics within 1 week prior to the first dose. Participants who are receiving or have received prophylactic antibiotics (e.g., prophylaxis against urinary infections) are allowed.\n\nLiver safety exclusion criteria:\n\n* Has an Alanine aminotransferase (ALT) value \\>2.5x upper limit of normal (ULN) or \\>5x ULN if documented history of liver metastases.\n* Has a total bilirubin value \\>1.5x ULN.\n* Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal\u002Fgastric varices, or persistent jaundice.\n* Has documented presence of Hepatitis B surface antigen (HBsAg), at screening or within 3 months prior to the first dose of study intervention.\n* Has a positive Hepatitis C virus (HCV) antibody test result at screening or within 3 months prior to Cycle 1 Day 1 unless the participant can meet the following criteria: NOTE: Participants with a positive HCV antibody test result due to prior resolved disease can be enrolled if a confirmatory negative HCV RNA test is obtained and the participant otherwise meets entry criteria\n* Has a positive HCV ribonucleic acid (RNA) test result at screening or within 3 months prior to the first dose of study intervention. NOTE: The HCV RNA test is optional, and participants with a negative HCV antibody test are not required to undergo HCV RNA testing as well.\n* Is unable to adhere to the protocol defined SoA, including requirements for the Follow-up Period of the study, study procedures, restrictions, and requirements as determined by the investigator.",{"count":54,"type":20},85,[23,24],"The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expansion phase).",[27],[59,60,61,62],"Metastatic castration-resistant prostate cancer (mCRPC)","GSK5458514","Dose escalation","Dose expansion",{"date":36,"type":37},{"date":65,"type":37},"2025-06-12",{"date":67,"type":20},"2028-08-09",{"name":43,"class":44},19,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":102},"100599460","investigation-of-impact-of-ai-on-prostate-cancer-workflow-100599460","NCT07084779","Investigation of Impact of AI on Prostate Cancer Workflow","Inclusion Criteria:\n\n* Plan of care is to undergo a biopsy of the prostate after a pre-biopsy MRI\n* Age 55-80\n* Prostate-specific antigen (PSA) between 3-10 ng\u002FmL\n* No prior diagnosis or treatment of prostate cancer\n\nExclusion Criteria:\n\n* Pre-biopsy MRI is of low quality\n* PI-QUAL score of 1 using PI-QUAL version 2","ALL","55 Years","80 Years",{"count":80,"type":20},150,[82],"NA","This study will enroll participants who are undergoing an MRI before a prostate biopsy due to suspected prostate cancer. The purpose of this study is to see if the use of Artificial Intelligence (AI) helps detect lesions on an MRI better than a radiologist not using AI. The AI Rad Companion (AIRC) Prostate MRI application is a software that uses measurements of the prostate and will be utilized in this study to help detect potential cancerous lesions. The AI software will assign the lesions a PI-RADS score, which is a way to measure the chance of the lesion being cancer.\n\nThere are two parts to this study. The first part involves comparing the interpretation of prostate MRI images by a radiologist alone, a radiologist aided by AI, and AI alone. A systematic biopsy will be completed per standard of care. The radiologist may opt to include up to 2 additional AI-identified targets to biopsy in addition to those biopsied for standard of care.\n\nThe second part of the study involves utilizing the MRI images from the first part of the study in addition to retrospective prostate MRI images. These de-identified images, along with Prostate Image Quality (PI-QUAL) scores, clinical data, and biopsy results will be sent to Siemens in order to aid in the development of methods to identify good or bad image quality in prostate MRI images.",[85,86,87,27],"Prostate Cancer","Prostatic Neoplasm","Cancer of the Prostate",[89,90,91],"Artificial Intelligence","Magnetic Resonance Imaging","Biopsy","2026-05-13",{"date":94,"type":37},"2026-05-15",{"date":96,"type":37},"2025-09-09",{"date":98,"type":20},"2026-11-30",{"name":100,"class":101},"Case Comprehensive Cancer Center","OTHER",1,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":112,"targetDuration":114,"studyType":115,"phases":4,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":102},"100457794","mriultrasound-fusion-guided-laser-ablation-of-prostate-cancer-100457794","NCT05241236","MRI\u002FUltrasound Fusion Guided Laser Ablation of Prostate Cancer","Office Based MRI\u002FUltrasound Guided Prostate Cancer Ablation: Outcomes Registry","MRFLA","Inclusion Criteria:\n\n* Men between 50 and 65 years of age with a clinical diagnosis of prostate cancer with Low or Intermediate risk prostate cancer, and \\\u003C50% positive core rate by prostate lobe\n* Men older than 65 years of age with clinical diagnosis of prostate cancer \\\u003C50% positive core rate by prostate lobe\n* Absence of extra-capsular extension\n* Absence of seminal vesicle invasion\n* Absence of regional or distant metastatic disease\n* Multiparametric MRI of the prostate performed either before the biopsy or \\>10 weeks after prostate biopsy\n* Treated with Cryotherapy of the prostate\n* Treatment based on co-registration between MP-MRI and Prostate Ultrasound\n\nExclusion Criteria:\n\n* Prior treatment of prostate cancer in the form of surgery.\n* Performance status greater than 0 based on ECOG criteria\n* Mental status impairment","50 Years",{"count":113,"type":20},5000,"10 Years","OBSERVATIONAL","This serves as a registration trial. It aims to record short, intermediate, and long-term outcomes of patients treated with targeted laser ablation of biopsy confirmed prostate cancer. Outcomes will be categorized as: 1- Procedure Related, 2- Perioperative - Adverse Events that may occur within 90 days, 3-Oncologic: Recurrence of cancer in treatment area, de-novo tumors, conversion to radical surgery, radiation or cryoablation, emergence of metastasis, 4- Functional: Sexual and Urinary function following treatment",[118,87],"Neoplasms Prostate",[120,121,122,123,124,125,126,127,128,129,130,131],"Prostate","PSA","FUSION","Ultrasound","MRI","Cancer","Laser","Outcomes","Recurrence","QOL, Quality of Life","Urinary function","Sexual Function","2023-01-24",{"date":134,"type":37},"2023-01-26",{"date":136,"type":37},"2020-11-15",{"date":138,"type":20},"2038-11",{"name":140,"class":101},"Urological Research Network, LLC",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":149,"targetDuration":114,"studyType":115,"phases":4,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":154,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":102},"100238430","mriultrasound-fusion-guided-prostate-cryotherapy-100238430","NCT02381990","MRI\u002FUltrasound Fusion Guided Prostate Cryotherapy","Office Based MRI\u002FUltrasound Guided Prostate Cryotherapy: Outcomes Registry","FIPC","Inclusion Criteria:\n\n* Men between 55 and 65 years of age with a clinical diagnosis of prostate cancer with Low or Intermediate risk prostate cancer, and \\\u003C50% positive core rate by prostate lobe\n* Men older than 65 years of age with clinical diagnosis of prostate cancer \\\u003C50% positive core rate by prostate lobe\n* Absence of extra-capsular extension\n* Absence of seminal vesicle invasion\n* Absence of regional or distant metastatic disease\n* Multiparametric MRI of the prostate performed either before the biopsy or \\>10 weeks after prostate biopsy\n* Treated with Cryotherapy of the prostate\n* Treatment based on co-registration between MP-MRI and Prostate Ultrasound\n\nExclusion Criteria:\n\n* Prior treatment of prostate cancer in the form of surgery.\n* Performance status greater than 0 based on ECOG criteria\n* Mental status impairment",{"count":113,"type":20},"Registration of Prostate Cancer patients undergoing Prostate Cryotherapy guided by Mutiparametric-MRI (MP-MRI) highlighting biopsy confirmed regions. The primary outcome measure is 5 year oncological control. Secondary aim is lack of progression beyond the prostate gland. The aim of intervention is to eradicate prostate cancer disease in the treated area while imposing no or minimal deleterious effects in quality of life.",[118,87],[120,121,122,123,124,125,153,127,128,129,130,131],"Cryotherapy",{"date":134,"type":37},{"date":156,"type":37},"2013-08",{"date":158,"type":20},"2033-08",{"name":140,"class":101}]